384 related articles for article (PubMed ID: 9392540)
41. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.
Roach M; Lu J; Pilepich MV; Asbell SO; Mohiuddin M; Grignon D
J Urol; 2003 Jan; 169(1):245-50. PubMed ID: 12478146
[TBL] [Abstract][Full Text] [Related]
42. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
43. Clinical utility of endorectal MRI in determining PSA outcome for patients with biopsy Gleason score 7, PSA Cheng GC; Chen MH; Whittington R; Malkowicz SB; Schnall MD; Tomaszewski JE; D'Amico AV
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):64-70. PubMed ID: 12504037
[TBL] [Abstract][Full Text] [Related]
44. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
[TBL] [Abstract][Full Text] [Related]
45. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.
Lawton CA; Winter K; Murray K; Machtay M; Mesic JB; Hanks GE; Coughlin CT; Pilepich MV
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):937-46. PubMed ID: 11240234
[TBL] [Abstract][Full Text] [Related]
46. A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy.
Green GA; Hanlon AL; Al-Saleem T; Hanks GE
Cancer; 1998 Sep; 83(5):971-6. PubMed ID: 9731902
[TBL] [Abstract][Full Text] [Related]
47. Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995.
Preston DM; Bauer JJ; Connelly RR; Sawyer T; Halligan J; Leifer ES; McLeod DG; Moul JW
Urology; 1999 Jan; 53(1):131-8. PubMed ID: 9886602
[TBL] [Abstract][Full Text] [Related]
48. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
D'Amico AV; Manola J; Loffredo M; Renshaw AA; DellaCroce A; Kantoff PW
JAMA; 2004 Aug; 292(7):821-7. PubMed ID: 15315996
[TBL] [Abstract][Full Text] [Related]
49. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.
Alexander A; Crook J; Jones S; Malone S; Bowen J; Truong P; Pai H; Ludgate C
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):23-30. PubMed ID: 19395187
[TBL] [Abstract][Full Text] [Related]
50. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
Eulau SM; Tate DJ; Stamey TA; Bagshaw MA; Hancock SL
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):735-40. PubMed ID: 9652832
[TBL] [Abstract][Full Text] [Related]
51. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Pilepich MV; Winter K; John MJ; Mesic JB; Sause W; Rubin P; Lawton C; Machtay M; Grignon D
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1243-52. PubMed ID: 11483335
[TBL] [Abstract][Full Text] [Related]
52. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
53. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
Labrie F; Candas B; Gomez JL; Cusan L
Urology; 2002 Jul; 60(1):115-9. PubMed ID: 12100935
[TBL] [Abstract][Full Text] [Related]
54. Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter.
D'Amico AV; Whittington R; Kaplan I; Beard C; Schultz D; Malkowicz SB; Wein A; Tomaszewski JE; Coleman CN
Cancer; 1998 Jan; 82(2):334-41. PubMed ID: 9445191
[TBL] [Abstract][Full Text] [Related]
55. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
[TBL] [Abstract][Full Text] [Related]
56. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
D'Amico AV; Saegaert T; Chen MH; Renshaw AA; George D; Oh W; Kantoff PW
Cancer; 2002 Jul; 95(2):275-80. PubMed ID: 12124826
[TBL] [Abstract][Full Text] [Related]
57. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis.
Livsey JE; Cowan RA; Wylie JP; Swindell R; Read G; Khoo VS; Logue JP
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1254-9. PubMed ID: 14630259
[TBL] [Abstract][Full Text] [Related]
58. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer.
Laverdière J; Nabid A; De Bedoya LD; Ebacher A; Fortin A; Wang CS; Harel F
J Urol; 2004 Mar; 171(3):1137-40. PubMed ID: 14767287
[TBL] [Abstract][Full Text] [Related]
59. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
60. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
Gomella LG; Liberman SN; Mulholland SG; Petersen RO; Hyslop T; Corn BW
Urology; 1996 Jun; 47(6):870-7. PubMed ID: 8677579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
